After layoffs, BridgeBio turns to dealmaking for up to 6 drugs
After layoffs, BridgeBio turns to dealmaking for up to 6 [...]
After layoffs, BridgeBio turns to dealmaking for up to 6 [...]
Chutes & Ladders—Biogen CEO Vounatsos steps down amid company overhaul [...]
Intellia puts pedal to the metal as 3 new candidates [...]
BioCryst’s voluntary pause turns FDA-hold as investigation reveals likely culprit [...]
Big pharma resisting temptation for biotech M&A spree until prices [...]
Bavarian Nordic’s COVID-19 vaccine holds up against omicron in phase [...]
Bancel has ‘never been as busy’ amid M&A talks as [...]
Apnimed closes $62.5M series C after working tirelessly on lead [...]
Kezar scarred as midphase autoimmune blowup raises doubts about pipeline-in-a-drug [...]
Another Pfizer gene therapy is free of FDA hold, but [...]